STIM Revenue Flow
Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.
- 2026-06-30: Revenue $41.57M; Cost of revenue $20.34M; Research and development $1.34M; Selling, general and administrative (m).
- 2026-03-31: Revenue $34.45M; Cost of revenue $18.30M; Research and development $1.36M; Selling, general and administrative (m).
- 2025-12-31: Revenue $41.78M*; Cost of revenue $20.07M*; Research and development $1.67M*; Selling, general and administrative (m).
- 2025-09-30: Revenue $37.30M; Cost of revenue $20.19M; Research and development $1.50M; Selling, general and administrative (m).
Consolidation item
Separate filed amounts; connecting flows are not established. Components and totals may overlap.
Product or service
Separate filed amounts; connecting flows are not established. Components and totals may overlap.
Geography
Separate filed amounts; connecting flows are not established. Components and totals may overlap.
Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.
Historical revenue and expense breakdown
Revenue and expense 3 month
| Period end | Revenue | Cost of revenue | Research and development | Selling, general and administrative | Operating expenses | Income tax | Net income |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $41.57M | $20.34M | $1.34M | (m) | $22.72M | (m) | -$3.44M |
| 2026-03-31 | $34.45M | $18.30M | $1.36M | (m) | $25.15M | (m) | -$10.79M |
| 2025-12-31 | $41.78M* | $20.07M* | $1.67M* | (m) | $26.75M* | (m) | -$7.16M* |
| 2025-09-30 | $37.30M | $20.19M | $1.50M | (m) | $24.43M | (m) | -$9.04M |
| 2025-06-30 | $38.11M | $20.35M | $1.80M | (m) | $25.82M | (m) | -$10.12M |
| 2025-03-31 | $31.98M | $16.24M | $1.62M | (m) | $26.75M | (m) | -$12.68M |
| 2024-09-30 | $18.53M | $4.53M | $2.42M | $6.29M | $21.73M | $0.00 | -$13.34M |
| 2024-06-30 | $16.45M | $4.27M | $2.23M | (m) | $20.69M | (m) | -$9.83M |
| 2024-03-31 | $17.42M | $4.33M | $2.35M | (m) | $19.95M | (m) | -$7.87M |
| 2023-09-30 | $17.36M | $18.48M | $137.77K | $5.99M | $20.64M | $0.00 | -$13.49M |
| 2023-06-30 | $17.61M | $4.84M | $2.36M | (m) | $20.12M | (m) | -$4.90M |
| 2023-03-31 | $15.54M | $4.14M | $2.79M | (m) | $21.30M | (m) | -$10.52M |
| 2022-09-30 | $16.50M | $3.57M | $2.35M | (m) | $20.38M | (m) | -$7.61M |
| 2022-06-30 | $16.33M | $4.04M | $2.04M | (m) | $22.09M | (m) | -$10.42M |
| 2022-03-31 | $14.18M | $3.48M | $1.80M | (m) | $20.83M | (m) | -$10.84M |
| 2021-09-30 | $13.80M | $3.14M | $1.57M | (m) | $17.84M | (m) | -$8.15M |
| 2021-06-30 | $14.20M | $2.75M | $2.29M | (m) | $18.02M | (m) | -$7.53M |
| 2021-03-31 | $12.29M | $2.22M | $2.31M | (m) | $16.98M | (m) | -$7.88M |
| 2020-12-31 | $15.58M | $3.76M | $2.11M | (m) | $14.48M | (m) | -$3.66M |
| 2020-09-30 | $12.45M | $2.66M | $1.95M | (m) | $12.21M | (m) | -$3.42M |
| 2020-06-30 | $9.74M | $2.32M | $2.12M | (m) | $14.28M | (m) | -$7.76M |
| 2020-03-31 | $11.48M | $2.81M | $3.02M | (m) | $19.03M | (m) | -$12.61M |
| 2019-12-31 | $17.36M | $4.22M | $4.25M | (m) | $20.08M | (m) | -$7.55M |
| 2019-09-30 | $16.00M | $4.19M | $3.49M | (m) | $18.14M | (m) | -$6.87M |
| 2019-06-30 | $16.57M | $4.17M | $3.22M | (m) | $19.01M | (m) | -$7.09M |
| 2019-03-31 | $12.73M | $2.81M | $2.79M | (m) | $16.98M | (m) | -$7.53M |
| 2018-12-31 | $15.63M | $3.71M | $2.22M | (m) | $17.59M | (m) | -$6.14M |
| 2018-09-30 | $13.74M | $3.03M | $2.13M | (m) | $15.04M | (m) | -$4.96M |
| 2018-06-30 | $13.25M | $3.25M | $2.33M | (m) | $15.24M | (m) | -$7.50M |
| 2018-03-31 | $10.15M | $2.46M | $1.55M | (m) | $12.30M | (m) | -$5.50M |
| 2017-12-31 | $12.11M | $2.96M | $1.92M | (m) | $13.38M | (m) | -$4.92M |
| 2017-09-30 | $10.49M | $2.64M | $1.84M | (m) | $10.66M | (m) | -$3.75M |
| 2017-06-30 | $10.31M | $2.50M | $2.15M | (m) | $10.38M | (m) | -$2.87M |
| 2017-03-31 | $7.53M | $1.54M | $2.03M | (m) | $9.98M | (m) | -$4.51M |
Revenue and expense 6 month
| Period end | Revenue | Cost of revenue | Research and development | Operating expenses | Net income |
|---|---|---|---|---|---|
| 2026-06-30 | $76.02M | $38.65M | $2.70M | $47.87M | -$14.23M |
| 2025-06-30 | $70.08M | $36.59M | $3.41M | $52.57M | -$22.80M |
| 2024-06-30 | $33.87M | $8.60M | $4.58M | $40.63M | -$17.70M |
| 2023-06-30 | $33.15M | $8.98M | $5.15M | $41.43M | -$15.42M |
| 2022-06-30 | $30.51M | $7.52M | $3.85M | $42.92M | -$21.26M |
| 2021-06-30 | $26.49M | $4.97M | $4.60M | $34.99M | -$15.41M |
| 2020-06-30 | $21.22M | $5.13M | $5.14M | $33.31M | -$20.38M |
| 2019-06-30 | $29.30M | $6.98M | $6.01M | $35.98M | -$14.62M |
| 2018-06-30 | $23.40M | $5.70M | $3.88M | $27.54M | -$12.99M |
| 2017-06-30 | $17.83M | $4.04M | $4.17M | $20.36M | -$7.38M |
Revenue and expense 9 month
| Period end | Revenue | Cost of revenue | Research and development | Selling, general and administrative | Operating expenses | Income tax | Net income |
|---|---|---|---|---|---|---|---|
| 2025-09-30 | $107.38M | $56.78M | $4.92M | (m) | $77.00M | (m) | -$31.84M |
| 2024-09-30 | $52.40M | $13.13M | $7.00M | $21.47M | $62.36M | $0.00 | -$31.05M |
| 2023-09-30 | $54.36M | $57.17M | $355.83K | $21.41M | $62.06M | $0.00 | -$36.82M |
| 2022-09-30 | $47.01M | $11.09M | $6.20M | (m) | $63.30M | (m) | -$28.87M |
| 2021-09-30 | $40.29M | $8.12M | $6.18M | (m) | $52.83M | (m) | -$23.56M |
| 2020-09-30 | $33.66M | $7.79M | $7.09M | (m) | $45.52M | (m) | -$23.80M |
| 2019-09-30 | $45.30M | $11.17M | $9.50M | (m) | $54.12M | (m) | -$21.49M |
| 2018-09-30 | $37.14M | $8.74M | $6.01M | (m) | $42.58M | (m) | -$17.95M |
| 2017-09-30 | $28.32M | $6.67M | $6.02M | (m) | $31.02M | (m) | -$11.13M |
Revenue and expense 12 month
| Period end | Revenue | Cost of revenue | Research and development | Operating expenses | Net income |
|---|---|---|---|---|---|
| 2025-12-31 | $149.16M | $76.85M | $6.58M | $103.74M | -$39.00M |
| 2024-12-31 | $74.89M | $20.73M | $12.77M | $88.72M | -$43.71M |
| 2023-12-31 | $71.35M | $19.64M | $9.52M | $82.26M | -$30.19M |
| 2022-12-31 | $65.21M | $15.48M | $9.34M | $84.83M | -$37.16M |
| 2021-12-31 | $55.31M | $11.65M | $7.92M | $71.22M | -$31.19M |
| 2020-12-31 | $49.24M | $11.55M | $9.20M | $60.00M | -$27.45M |
| 2019-12-31 | $62.66M | $15.39M | $13.75M | $74.20M | -$29.04M |
| 2018-12-31 | $52.78M | $12.45M | $8.23M | $60.16M | -$24.10M |
| 2017-12-31 | $40.43M | $9.63M | $7.94M | $44.41M | -$16.06M |
| 2016-12-31 | $34.23M | $6.62M | $8.22M | $36.94M | -$11.23M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Profound Medical Corp. (PROF) | $0.206B | -7.37 | |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Lucid Diagnostics Inc. (LUCD) | United States | $0.170B | |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| KORU Medical Systems, Inc. (KRMD) | United States | $0.151B | -106.78 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |